Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an Australian experience - effective, safe, yet room for improvement

Ayushi Chauhan; Ross Apostolov; Daniel van Langenberg; Mayur Garg

doi:10.1111/imj.15162

Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an Australian experience - effective, safe, yet room for improvement

Intern Med J. 2021 Jan;51(1):106-110. doi: 10.1111/imj.15162.

Authors

Ayushi Chauhan¹, Ross Apostolov¹, Daniel van Langenberg^{1

2}, Mayur Garg^{1

2

3

4}

Affiliations

¹ Department of Gastroenterology, Eastern Health, Melbourne, Victoria, Australia.
² Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.
³ Department of Gastroenterology and Hepatology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
⁴ Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.

PMID: 33572016
DOI: 10.1111/imj.15162

Abstract

Faecal microbiota transplantation (FMT) is reportedly effective and safe for the management of recurrent or refractory Clostridioides difficile infection (CDI), yet real-world data of outcomes of FMT in Australia are limited. In this series, FMT safely resulted in resolution of CDI in 19 patients with reduced healthcare utilisation after 25 FMT, but one patient was diagnosed with an anti-nuclear antibody-positive constitutional illness and Hashimoto thyroiditis following FMT. Further prospective evaluation of the utility of FMT earlier in CDI treatment algorithms to minimise cost and morbidity, and recipient follow up for immune-mediated conditions, is required.

Keywords: ANA; Clostridioides difficile; faecal microbiota transplantation; host−microbiota interaction; immune-mediated illness.

MeSH terms

Australia
Clostridioides
Clostridioides difficile*
Clostridium Infections* / diagnosis
Clostridium Infections* / therapy
Fecal Microbiota Transplantation
Humans
Recurrence
Treatment Outcome